Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:GWPH NASDAQ:IONS NASDAQ:SRPT NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$16.76-11.1%$16.34$9.57▼$29.86$2.60B0.931.58 million shs3.01 million shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AIONSIonis Pharmaceuticals$41.76-1.0%$37.30$23.95▼$52.34$6.71B0.231.62 million shs1.27 million shsSRPTSarepta Therapeutics$14.07-36.0%$28.42$11.90▼$150.48$2.16B0.452.70 million shs76.79 million shsUTHRUnited Therapeutics$292.01-1.8%$300.42$266.98▼$417.82$13.41B0.53442,150 shs322,671 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+3.01%-0.05%+21.61%+67.70%-32.73%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IONSIonis Pharmaceuticals-1.40%-0.50%+16.65%+48.49%-12.07%SRPTSarepta Therapeutics+19.53%+15.21%+1.90%-59.16%-85.04%UTHRUnited Therapeutics-0.28%-0.94%+3.64%+4.43%-10.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.8607 of 5 stars3.42.00.03.43.71.70.0GWPHGW PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIONSIonis Pharmaceuticals4.4718 of 5 stars4.42.00.03.02.13.30.6SRPTSarepta Therapeutics4.8303 of 5 stars4.22.00.04.22.91.72.5UTHRUnited Therapeutics4.9873 of 5 stars4.35.00.04.63.43.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71160.83% UpsideGWPHGW Pharmaceuticals 0.00N/AN/AN/AIONSIonis Pharmaceuticals 2.76Moderate Buy$57.1336.81% UpsideSRPTSarepta Therapeutics 2.40Hold$56.50301.56% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$383.0831.19% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, UTHR, IONS, SRPT, and GWPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold7/18/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$28.00 ➝ $20.007/18/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $41.007/17/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform7/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.007/17/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$29.00 ➝ $32.007/17/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$25.00 ➝ $23.007/17/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$50.007/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $35.007/10/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.007/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$348.00 ➝ $328.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M651.99N/AN/A$1.54 per share10.88GWPHGW Pharmaceuticals$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33IONSIonis Pharmaceuticals$705M9.43N/AN/A$3.73 per share11.20SRPTSarepta Therapeutics$1.90B0.73$1.56 per share9.02$15.99 per share0.88UTHRUnited Therapeutics$2.88B4.58$27.89 per share10.47$144.34 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/A22.17N/A-45.33%-12.49%8/6/2025 (Estimated)GWPHGW Pharmaceuticals-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/AIONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.29N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.0611.6510.626.4340.44%19.33%16.73%7/30/2025 (Estimated)Latest ARWR, UTHR, IONS, SRPT, and GWPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94N/AN/AN/AN/AN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89N/AN/AN/A$530.66 millionN/A7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19N/AN/AN/A$270.90 millionN/A7/30/2025Q2 2025UTHRUnited Therapeutics$6.89N/AN/AN/A$802.13 millionN/A5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.315.155.15GWPHGW Pharmaceuticals0.015.134.31IONSIonis Pharmaceuticals2.639.669.62SRPTSarepta Therapeutics1.004.022.46UTHRUnited TherapeuticsN/A5.465.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%GWPHGW Pharmaceuticals81.00%IONSIonis Pharmaceuticals93.86%SRPTSarepta Therapeutics86.68%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%GWPHGW Pharmaceuticals3.10%IONSIonis Pharmaceuticals2.60%SRPTSarepta Therapeutics7.70%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million132.16 millionOptionableGWPHGW Pharmaceuticals1,16131.35 millionN/AOptionableIONSIonis Pharmaceuticals1,069159.16 million155.02 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableARWR, UTHR, IONS, SRPT, and GWPH HeadlinesRecent News About These CompaniesMorgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating4 hours ago | msn.comHere's Why United Therapeutics (UTHR) is a Strong Value StockJuly 18 at 10:40 AM | zacks.comHussman Strategic Advisors Inc. Boosts Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 18 at 10:38 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Purchased by Victory Capital Management Inc.July 18 at 6:27 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 18 at 2:57 AM | americanbankingnews.comUnited Therapeutics Corporation (NASDAQ:UTHR) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 18 at 2:56 AM | marketbeat.comUnited Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025July 16 at 7:00 AM | businesswire.comEnvestnet Asset Management Inc. Increases Stake in United Therapeutics Corporation (NASDAQ:UTHR)July 16 at 3:43 AM | marketbeat.comUnpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics StocksJuly 15 at 8:37 AM | finance.yahoo.comMQS Management LLC Purchases New Position in United Therapeutics Corporation (NASDAQ:UTHR)July 15 at 5:38 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by M&T Bank CorpJuly 15 at 4:27 AM | marketbeat.comPaul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) StockJuly 14, 2025 | marketbeat.com6,585 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Bought by Aurora Investment CounselJuly 14, 2025 | marketbeat.comEmerald Advisers LLC Sells 1,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 14, 2025 | marketbeat.comMorgan Stanley Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $328.00July 13, 2025 | americanbankingnews.comNisa Investment Advisors LLC Sells 4,544 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 12, 2025 | marketbeat.comUnited Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension ResearchJuly 11, 2025 | tipranks.comWhy United Therapeutics (UTHR) is a Top Growth Stock for the Long-TermJuly 11, 2025 | zacks.comWeil Company Inc. Buys 3,298 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 11, 2025 | marketbeat.com1,822 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Rehmann Capital Advisory GroupJuly 11, 2025 | marketbeat.comUBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)July 10, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAnalysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge Potential3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings SeasonPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersARWR, UTHR, IONS, SRPT, and GWPH Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$16.76 -2.09 (-11.09%) Closing price 04:00 PM EasternExtended Trading$16.86 +0.10 (+0.60%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.GW Pharmaceuticals NASDAQ:GWPHGW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Ionis Pharmaceuticals NASDAQ:IONS$41.76 -0.41 (-0.97%) Closing price 04:00 PM EasternExtended Trading$41.76 +0.01 (+0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Sarepta Therapeutics NASDAQ:SRPT$14.07 -7.90 (-35.96%) Closing price 04:00 PM EasternExtended Trading$13.38 -0.70 (-4.94%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.United Therapeutics NASDAQ:UTHR$292.01 -5.32 (-1.79%) Closing price 04:00 PM EasternExtended Trading$291.00 -1.01 (-0.35%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
